Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020)
Larimar Therapeutics' (LRMR) quarterly Other Operating Expenses came in at -$10000.0 in Q1 2020, up 97.57% quarter-over-quarter from -$411000.0 in Q4 2019.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020) Analysis & Trends
Larimar Therapeutics (LRMR) has reported Other Operating Expenses for 2 consecutive years, with -$10000.0 the latest figure, recorded in Q1 2020.
- For the quarter ending Q1 2020, Other Operating Expenses changed N/A year-over-year to -$10000.0; the trailing twelve-month figure through Dec 2020 stood at -$10000.0 (up 99.77% YoY), and the FY2019 full-year result was -$5.6 million, changed N/A from the prior year.
- Other Operating Expenses improved to -$10000.0 in Q1 2020 per LRMR's latest filing, from -$411000.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at -$10000.0 in Q1 2020 and bottomed at -$4.0 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Larimar Therapeutics | 397.87 Mn | 241.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | -10,000.00 |
| Dec 31, 2019 | -411,000.00 |
| Sep 30, 2019 | -4.02 Mn |